Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systemic Therapy for Melanoma: ASCO Guideline Update
Rahul Seth, Sanjiv S. Agarwala, Hans Messersmith, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 30, pp. 4794-4820
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
Lingjiao Meng, Haotian Wu, Jiaxiang Wu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 57
Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances
Hyun Jee Kim, Yeong Ho Kim
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2984-2984
Open Access | Times Cited: 21
An Evaluation of Sentinel Lymph Node Biopsy Guideline Adherence in Melanoma
Adriana Doren, Hemali Shah, Ashar Ata, et al.
Annals of Surgical Oncology (2025)
Closed Access | Times Cited: 2
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase 3 KEYNOTE-006 study
Georgina V. Long, M.S. Carlino, Catriona M. McNeil, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 15
Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy
Carl A. Shirley, Gagan Chhabra, Deeba Amiri, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Same‐day molecular testing for targetable mutations in solid tumor cytopathology—The next frontier of the rapid on‐site evaluation
J. Bryan Iorgulescu, Richard K. Yang, Sinchita Roy‐Chowdhuri, et al.
Cancer Cytopathology (2025) Vol. 133, Iss. 1
Open Access | Times Cited: 1
Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy
Teresa Amaral, Eftychia Chatziioannou, A. Nuebling, et al.
European Journal of Cancer (2025), pp. 115372-115372
Open Access | Times Cited: 1
Uveal melanoma: Recent advances in immunotherapy
Francesco Saverio Sorrentino, Francesco De Rosa, Patrick Di Terlizzi, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 1, pp. 23-31
Open Access | Times Cited: 7
Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance
Michele Dei, Chiara Maura Ciniselli, Elisabetta Vergani, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1558-1558
Open Access | Times Cited: 7
Metastatic Nodular Melanoma with Angiosarcomatous Transdifferentiation—A Case Report and Review of the Literature
Adrian Dumitru, Dana Antonia Țăpoi, Mariana Costache, et al.
Diagnostics (2024) Vol. 14, Iss. 13, pp. 1323-1323
Open Access | Times Cited: 5
Prognostic and predictive biomarkers in melanoma
Nigel Maher, Ismael A. Vergara, Georgina V. Long, et al.
Pathology (2023) Vol. 56, Iss. 2, pp. 259-273
Closed Access | Times Cited: 11
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB
Teresa Amaral, Lena Nanz, Rudolf Stadler, et al.
European Journal of Cancer (2024) Vol. 201, pp. 113912-113912
Open Access | Times Cited: 4
Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node
Rossella Scardaci, Ewa Berlinska, Pietro Scaparone, et al.
Molecular Oncology (2024) Vol. 18, Iss. 6, pp. 1355-1377
Open Access | Times Cited: 4
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
Domenico Mallardo, Francesca Sparano, Maria Grazia Vitale, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 8
Open Access | Times Cited: 4
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Jessica S.W. Borgers, Divya Lenkala, Victoria Kohler, et al.
Nature Medicine (2025)
Open Access
Size-specific clonidine-loaded liposomes: Advancing melanoma microenvironment suppression with safety and precision
Nianzhou Yu, Yantao Xu, Qi Sun, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 120-134
Closed Access
Case Report: Can You See the Elephant in the Room? Skin Melanoma Revealed by Gastric Metastasis
Ramzi Tababi, A Khsiba, Moufida Mahmoudi, et al.
F1000Research (2025) Vol. 13, pp. 1019-1019
Open Access
Female Oncofertility and Immune Checkpoint Blockade in Melanoma: Where Are We Today?
Cha Len Lee, Erika Martínez, Diego Malón, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 238-238
Open Access
Metastatic Melanoma to Ovary and Advances in Metastatic Melanoma Treatment: A Case Report
M Cantave, Anita H. Chen, Aakriti R. Carrubba, et al.
Cureus (2025)
Open Access
Oronasal mucosal melanoma is defined by two transcriptional subtypes in humans and dogs with implications for diagnosis and therapy
Kelly Bowlt, Kevin S. Donnelly, Yuting Lu, et al.
The Journal of Pathology (2025)
Open Access
Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: a phase 2 trial
J. Doyen, A. Dompmartin, Coralie Cruzel, et al.
European Journal of Cancer (2025) Vol. 217, pp. 115256-115256
Closed Access
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study
Nargız Majidova, Hacı Arak, Faruk Özalp, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
A Review and Comparison of Immune-Checkpoint Inhibitors in the Treatment of Metastatic Uveal Melanoma
Benyamin Alam, Amir Reza Akbari, Ahmed Ageed, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 885-885
Open Access
Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma
Marek Pásek, Eva Sticová, Emanuel Marques, et al.
Dermatology Practical & Conceptual (2025) Vol. 15, Iss. 1, pp. 4967-4967
Open Access
Size matters: early progression of melanoma brain metastases after treatment with immune checkpoint inhibitors
Sophie H. A. E. Derks, Li Shen Ho, Stephan R Koene, et al.
Neuro-Oncology Advances (2025) Vol. 7, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top